Similar articles

• Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

  Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Llibre JM, et al. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310899 Clinical Trial.
• Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.

  Hester EK, Astle K. Hester EK, et al. Ann Pharmacother. 2019 Aug;53(8):860-866. doi: 10.1177/1060028019831674. Epub 2019 Feb 13. Ann Pharmacother. 2019. PMID: 30758229 Review.
• Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.

  Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti-Foppa C, Castagna A, D'Avolio A, Lazzarin A, Bonora S, Hasson H. Merli M, et al. J Antimicrob Chemother. 2017 Mar 1;72(3):812-815. doi: 10.1093/jac/dkw492. J Antimicrob Chemother. 2017. PMID: 27999010
• Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.

  Casado JL, Monsalvo M, Rojo AM, Fontecha M, Rodriguez-Sagrado MA. Casado JL, et al. Expert Rev Clin Pharmacol. 2018 Jun;11(6):561-570. doi: 10.1080/17512433.2018.1478726. Epub 2018 May 28. Expert Rev Clin Pharmacol. 2018. PMID: 29775399 Review.
• Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.

  Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M. Revuelta-Herrero JL, et al. Ann Pharmacother. 2018 Jan;52(1):11-18. doi: 10.1177/1060028017728294. Epub 2017 Aug 24. Ann Pharmacother. 2018. PMID: 28836468